DUBLIN, IRELAND – Dublin’s biotech and pharmaceutical companies seeking specialized preclinical contract research organization (CRO) services can accelerate their drug discovery timelines with Anilocus. We provide comprehensive preclinical research support specifically designed for Dublin’s dynamic life sciences ecosystem, delivering the regulatory expertise and scientific precision your projects demand.
Supporting the Dublin Life Sciences Powerhouse
Dublin stands as Ireland’s premier biotechnology hub and Europe’s third-largest pharmaceutical exporter. The Dublin region hosts over 90 pharmaceutical companies employing 50,000 people directly, with an additional 50,000 supported indirectly, generating €99.9 billion in annual pharmaceutical exports representing 45% of Ireland’s total goods exports. The cluster includes 24 of the world’s top 25 biotech and pharma companies, making it one of the most concentrated pharmaceutical ecosystems globally.
The city hosts major pharmaceutical giants including Pfizer, Novartis, AbbVie, Johnson & Johnson, and Eli Lilly, alongside innovative biotech companies like Prothena Corporation, Nuritas, SynOx Therapeutics, Allogen Biotech, and Dublin-based companies developing breakthrough therapies in neurodegenerative diseases, natural bioactive peptides, and advanced therapeutics. Dublin’s proximity to world-class research institutions including Trinity College Dublin, University College Dublin, and the National Institute for Bioprocessing Research and Training (NIBRT) creates an unparalleled environment for collaborative drug discovery and development.
Dublin’s position as Europe’s gateway to both US and global markets, combined with Ireland’s favorable 12.5% corporate tax rate and robust regulatory framework, provides unique advantages for companies targeting international markets with streamlined access to both EMA and FDA regulatory pathways. This established pharmaceutical cluster requires specialized CRO services to support the complex preclinical studies necessary for EMA, FDA, and international regulatory approval.
Why Dublin Biotech Companies Choose Anilocus
- EMA and FDA regulatory expertise – Deep understanding of Irish and European regulatory requirements alongside FDA compliance, ensuring smooth transitions from preclinical to clinical phases across multiple jurisdictions
- Specialized in vivo capabilities – Advanced in vivo assessments and custom study designs that complement Dublin’s strength in pharmaceutical innovation and bioprocessing excellence
- Integrated preclinical solutions – Comprehensive study design through regulatory submission support, reducing vendor management complexity and accelerating development timelines for Dublin biotech companies
Preclinical CRO Services
Anilocus delivers the full spectrum of preclinical research services that Dublin’s pharmaceutical industry demands. Our capabilities span multiple critical areas of drug development, from initial compound characterization through regulatory submission support.
Pharmacodynamics
Our pharmacodynamics studies determine the biochemical and physiological effects of compounds through receptor binding assays, enzyme inhibition assays, signal transduction assays, functional cell-based assays, and biomarker analysis. These investigations reveal how drug candidates interact with their molecular targets and produce therapeutic effects.
Pharmacokinetics
Pharmacokinetics research characterizes absorption, distribution, metabolism, and excretion properties using plasma concentration-time profiling, bioavailability assays, microsomal stability assays, permeability (Caco-2) assays, and blood-brain barrier penetration assays. This data is essential for understanding drug exposure and designing optimal dosing regimens.
Toxicology
Our toxicology studies assess potential adverse effects through acute toxicity assays, sub-chronic toxicity assays, chronic toxicity assays, maximum tolerated dose (MTD) assays, and no observed adverse effect level (NOAEL) determination. These comprehensive evaluations establish safe dose ranges and identify target organs of toxicity.
Safety Pharmacology
Safety pharmacology investigations examine effects on vital physiological systems using hERG channel inhibition assays, ECG telemetry assays, respiratory rate monitoring, locomotor activity assays, and core body temperature assays. This ensures drug candidates don’t adversely affect cardiovascular, respiratory, or central nervous system function.
Bioanalytics Testing for Dublin Biotech
Genotoxicity
Our genotoxicity studies evaluate genetic damage potential through Ames tests, in vitro micronucleus assays, chromosomal aberration assays, comet assays, and mouse lymphoma assays. These investigations are crucial for identifying compounds that might cause cancer or heritable defects.
Reprotox
Reproductive and developmental toxicology assessments examine drug impact on fertility and development using fertility and early embryonic development assays, embryo-fetal development assays, prenatal and postnatal development assays, teratogenicity assays, and sperm morphology assays. These studies ensure reproductive safety across generations.
Immunotoxicity
Our immunotoxicology services detect immune system effects through T-cell proliferation assays, natural killer cell activity assays, delayed-type hypersensitivity assays, hemagglutination titer assays, and cytokine release assays. This identifies potential immunosuppression, hypersensitivity, or autoimmunity risks.
Carcinogenicity
For compounds intended for chronic use, our carcinogenicity studies assess long-term tumor formation potential using rodent bioassays (2-year studies), initiation-promotion assays, transgenic mouse models (e.g., rasH2), cell transformation assays, and DNA adduct formation assays.
Ready to Accelerate Your Dublin Biotech Research?
Ready to advance your preclinical research with a CRO partner that understands Dublin’s pharmaceutical ecosystem and regulatory landscape? From Trinity College Dublin spinouts to established pharmaceutical companies in Ireland’s life sciences cluster, Anilocus delivers the scientific excellence that forward-thinking Dublin biotech companies demand.
Get Started Today!
Transform your research vision into actionable data with Anilocus, where scientific precision meets custom fabrication capability for real research impact. Contact us today and speak to a scientist about your Dublin biotech project!
Keep Reading
- Pfizer Invests €1.2 Billion in Dublin’s Grange Castle Biotech Facility Expansion – Learn how the pharmaceutical giant’s major investment strengthens Dublin’s position as a global biotechnology manufacturing hub.
- Trinity College Dublin Wins €31.6 Million ARC Hub for Therapeutics Initiative – Discover how Dublin’s premier university received Research Ireland funding to accelerate innovative therapeutic development and strengthen Ireland’s life sciences sector.
- NIBRT Hosts Annual Research Conference Bringing Together European Life Sciences Leaders – Explore how Dublin’s National Institute for Bioprocessing Research and Training connects academia, industry, and regulatory agencies for bioprocessing innovation.
- Dublin Biotech Nuritas Raises $35 Million for Natural Bioactive Peptide Discovery – Understand how Dublin-based biotechnology companies are attracting significant venture capital investment for breakthrough therapeutic platforms.
